本文转载自药创新作者:沛沛100多个自主创新产品正在临床开发,恒瑞如何分配资源?从肿瘤和特药起家,到如今布局心血管、代谢、自免等多个慢病领域,恒瑞医药的研发版图不断扩大,以创新研发硬实力奠定增长前景的同时,也用丰富的治疗产品组合填补未满足临床需求,革新治疗格局。出海进程亦在持续加速,已同默沙东、GSK、默克等跨国药企达成交易,超20项创新药国际临床试验正在进行,驶向“造船出海”的新目标。10月26...
Source Link本文转载自药创新作者:沛沛100多个自主创新产品正在临床开发,恒瑞如何分配资源?从肿瘤和特药起家,到如今布局心血管、代谢、自免等多个慢病领域,恒瑞医药的研发版图不断扩大,以创新研发硬实力奠定增长前景的同时,也用丰富的治疗产品组合填补未满足临床需求,革新治疗格局。出海进程亦在持续加速,已同默沙东、GSK、默克等跨国药企达成交易,超20项创新药国际临床试验正在进行,驶向“造船出海”的新目标。10月26...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.